LOXL4 and breast cancer: In the current study, we demonstrated that blocking EZH2 activity by EZH2 inhibitors or EZH2 siRNAs significantly reduced the expression of LOXL4 associated with low H3K27me3 expression, suggesting that coordinated epigenetic silencing may exist in breast cancer cells (Figure 1C-E; Figures S1A and S2).